Of note, although the incidence of hyperkalemia was slightly higher in finerenone group than placebo group, not many patients permanently discontinued the drug due to hyperkalemia (122/7331≈1.66%), which is significantly lower than the data on renin-angiotensin system blockers (39). This evidence concerns the gene REN and Hyperkalemia.